Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

被引：6

作者：

Gurbuz, Mustafa ^{[1
]}

Kutlu, Yasin ^{[2
]}

Akkus, Erman ^{[3
]}

Koksoy, Elif Berna ^{[1
]}

Kose, Naziyet ^{[4
]}

Oven, Bala Basak ^{[5
]}

Uluc, Basak Oyan ^{[6
]}

Demiray, Atike Gokcen ^{[7
]}

Erdem, Dilek ^{[8
]}

Demir, Bilgin ^{[9
]}

Turhal, Nazim Serdar ^{[10
]}

Uskent, Necdet ^{[10
]}

Akbas, Sinem ^{[11
]}

Selcukbiricik, Fatih ^{[11
]}

Inal, Ali ^{[12
]}

Bilici, Ahmet ^{[2
]}

Olmez, Omer Fatih ^{[2
]}

Cabuk, Devrim ^{[13
]}

Unal, Caglar ^{[14
]}

Hizal, Mutlu ^{[15
]}

Sendur, Mehmet Ali Nahit ^{[15
]}

Korkmaz, Mustafa ^{[16
]}

Karadurmus, Nuri ^{[17
]}

Erturk, Ismail ^{[17
]}

Goksu, Sema Sezgin ^{[18
]}

Tatli, Ali Murat ^{[18
]}

Guven, Deniz Can ^{[19
]}

Kilickap, Saadettin ^{[20
]}

Paksoy, Nail ^{[21
]}

Aydiner, Adnan ^{[21
]}

Cinkir, Havva Yesil ^{[22
]}

Ozkul, Ozlem ^{[23
]}

Ozturk, Akin ^{[24
]}

Balli, Sevinc ^{[1
]}

Kemal, Yasemin ^{[8
]}

Erdogan, Atike Pinar ^{[25
]}

Er, Ozlem ^{[26
]}

Yumuk, Perran Fulden ^{[11
]}

Demirkazik, Ahmet ^{[1
]}

机构：

[1] Ankara Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[2] Istanbul Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[3] Ankara Univ, Fac Med, Dept Internal Med, Ankara, Turkey

[4] Mem Ankara Hosp, Dept Med Oncol, Ankara, Turkey

[5] Bahcesehir Univ, Fac Med, Dept Med Oncol, Gortepe Med Pk Hosp, Istanbul, Turkey

[6] Acibadem Altunizade Hosp, Dept Med Oncol, Istanbul, Turkey

[7] Pamukkale Univ, Fac Med, Dept Med Oncol, Denizli, Turkey

[8] Samsun Med Pk Hosp, Dept Med Oncol, Samsun, Turkey

[9] Adnan Menderes Univ, Fac Med, Dept Med Oncol, Aydin, Turkey

[10] Anadolu Med Ctr, Dept Med Oncol, Kocaeli, Turkey

[11] Koc Univ Hosp, Dept Med Oncol, Istanbul, Turkey

[12] Mersin City Hosp, Dept Med Oncol, Mersin, Turkey

[13] Kocaeli Univ, Fac Med, Dept Med Oncol, Kocaeli, Turkey

[14] Gayrettepe Florence Nightingale Hosp, Dept Med Oncol, Istanbul, Turkey

[15] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[16] Necmettin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkey

[17] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey

[18] Akdeniz Univ, Fac Med, Dept Med Oncol, Antalya, Turkey

[19] Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[20] Istinye Univ, Liv Ankara Hosp, Fac Med, Dept Med Oncol, Ankara, Turkey

[21] Istanbul Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[22] Gaziantep Univ, Fac Med, Dept Med Oncol, Gaziantep, Turkey

[23] Bagcilar Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey

[24] Sureyyapasa Chest Dis & Thorac Surg Training & Re, Dept Med Oncol, Istanbul, Turkey

[25] Manisa Celal Bayar Univ, Dept Med Oncol, Fac Med, Manisa, Turkey

[26] Maslak Acibadem Hosp, Dept Med Oncol, Istanbul, Turkey

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2022年 / 148卷 / 12期

关键词：

Atezolizumab; Small cell lung cancer; Immunotherapy; PD-L1; ETOPOSIDE; PLATINUM;

D O I：

10.1007/s00432-022-04087-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.

引用

页码：3547 / 3555

页数：9

共 50 条

[21] Atezolizumab plus chemotherapy followed by atezolizumab plus anlotinib in the first-line treatment for extensive-stage small cell lung cancer: A multicenter, single-arm, prospective real-world study
Pan, Y.
Qian, X.
Zhou, H.
Jin, W.
Chen, J.
Wang, Y.
Zhang, Z.
Liu, H.
Jin, Y.
Jiang, F.
Liu, H.
ANNALS OF ONCOLOGY, 2024, 35 : S1071 - S1071
[22] Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options
Zugazagoitia, Jon
Paz-Ares, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 671 - +
[23] Efficacy analysis and prognostic factors of first-line chemotherapy combined with immunotherapy in extensive-stage small cell lung cancer: a real-world study
Jian-Xi Zhou
Yun-Chuan Sun
Li Xiao
Hong-Ling Lu
Xiao-Ming Yin
Kui Fan
Ying-Nan Zhou
Scientific Reports, 15 (1)
[24] Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Ding, Dong
Hu, Huabin
Li, Shuosha
Zhu, Youwen
Shi, Yin
Liao, Mengting
Liu, Jin
Tian, Xu
Liu, Aiting
Huang, Jin
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (10): : 1141 - +
[25] IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
Liu, S. V.
Horn, L.
Mok, T.
Mansfield, A.
De Boer, R.
Losonczy, G.
Sugawara, S.
Dziadziuszko, R.
Krzakowski, M.
Smolin, A.
Hochmair, M. J.
Garassino, M. C.
Lam, S.
McCleland, M.
Cardona, A.
Morris, S.
Reck, M.
ANNALS OF ONCOLOGY, 2020, 31 : S1032 - S1033
[26] Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
Yelena Ionova
Wilson Vuong
Omar Sandoval
Jodie Fong
Vincent Vu
Lixian Zhong
Leslie Wilson
Clinical Drug Investigation, 2022, 42 : 491 - 500
[27] Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
Ionova, Yelena
Vuong, Wilson
Sandoval, Omar
Fong, Jodie
Vu, Vincent
Zhong, Lixian
Wilson, Leslie
CLINICAL DRUG INVESTIGATION, 2022, 42 (06) : 491 - 500
[28] Phased avelumab combined with chemotherapy as first-line treatment in extensive stage small cell lung cancer (PAVE): A phase II Hellenic Cooperative Oncology Group study
Linardou, H.
Koliou, G-A.
Samantas, E.
Lampropoulou, D. I.
Spathas, N.
Fountzilas, E.
Christopoulou, A. N.
Psyrri, A.
Kosmas, E.
Vamvakaris, I.
Koumarianou, A.
Bafaloukos, D.
Fountzilas, G.
Mountzios, G.
ANNALS OF ONCOLOGY, 2021, 32 : S1163 - S1164
[29] Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
Zhou, Fei
Zhao, Wencheng
Gong, Xiaomei
Ren, Shengxiang
Su, Chunxia
Jiang, Tao
Zhou, Caicun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[30] Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer
Chen, Dawei
Gao, Aiqin
Zou, Bing
Huang, Wei
Shao, Qian
Meng, Xiangjiao
Zhang, Pinliang
Tang, Xiaoyong
Hu, Xudong
Zhang, Yan
Guo, Jun
Zhao, Wei
Fu, Lei
Zhao, Changhong
Yuan, Jiajia
Yu, Jinming
Wang, Linlin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →